You searched for "ocular"

1838 results found

Acute retinal necrosis presumably caused by Epstein-Barr virus infection

Acute retinal necrosis (ARN) is an uncommon, but serious and potentially blinding condition. ARN is characterised by panuveitis, occlusive vasculopathy and progressive peripheral necrotising retinitis. The diagnosis is clinical but confirmation is sought via aqueous and vitreous sampling. Varicella zoster...

Blurred vision post liver transplant: to blame the house cat or not?

This article outlines a case of atypical ocular toxoplasmosis associated with immunosuppression. There were two potential sources of infection in this patient and we describe how we concluded which was the most likely. Case report A 33-year-old female was referred...

Understanding and confronting bacterial endophthalmitis

Abdus Samad Ansari highlights the importance of early recognition of this condition using an unusual presentation. Endophthalmitis is a medical emergency with devastating consequences. Despite adequate treatment, severe cases frequently result in permanent blindness. Endophthalmitis involves inflammation of both the...

Vision Buddy: A sight enhancement wearable to enhance TV and computer viewing

This review of the Vision Buddy system continues our recent series on wearable assistive technology. The main component of the Vision Buddy system is a VR-type headset, designed to assist users with a range of tasks primarily within the home...

Therapy for limbal stem cell deficiency: cell fate after limbal stem cell transplants

“The beauty of scientific research lies in that the search for answers often yields yet more questions.” A large body of evidence points to the corneoscleral limbal location as the repository of putative epithelial stem cells [1]. Thoft proposed the...

Update on emerging therapies for age-related macular degeneration

The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...

Sustainability in eyecare: Are virtual clinics the way forward in the diagnosis and monitoring of retinal disease?

Virtual clinics can be used successfully in screening and management of ocular conditions such as diabetic retinopathy, retinopathy of prematurity and age-related macular degeneration. Virtual clinics should be a considered as a more clinically appropriate modality of consultation, diagnosis and...

Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service

Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...

21st Century retinal laser treatment in the anti-VEGF era

In today’s world, macular laser treatment has a vital role in the treatment of diabetic macular oedema (DMO). DMO is one of the most common causes of visual impairment. Despite expensive intravitreal treatment courses of anti-VEGF, many will agree that...

Sharing best practice and landmark evidence in glaucoma care

Evolving technology, best practice and landmark evidence in glaucoma care were reviewed by an international expert faculty in session presentations and debates during the 11th Moorfields International Glaucoma Symposium 2019. The authors were meeting chairs and provide an overview of...

Are we short-sighted about myopia?

Worldwide prevalence of myopia has increased rapidly in recent years and has now reached epidemic levels, particularly in South-East Asia where prevalence is around 80% [1-4]. Myopia prevalence is also increasing in the United States and Europe where it is...

“I can see fine. Why do I need my eyes tested?”

Are routine eye examinations really necessary? The author asks whether frequent appointments in low-risk patients with normal results are actually cost-effective. It’s recommended that most people should get their eyes tested every two years.” [1] This message is widely publicised...